Two trials explored the effect of immune-modulators on inflammation in people with HIV (PWH) on suppressive ART. A5336 (ruxolitinib vs placebo) revealed decreased immune activation (sCD14, CD38+HDR+ on CD4+ T Cells) and cell survival (Bcl-2). A5337 (sirolimus, single arm) revealed decreased cellular cycling (Ki67+) and CD4+ T-cell HIV DNA. Here, we investigate if these immune-modulators affect CMV DNA to elucidate a possible contributing effect of CMV replication on inflammatory outcomes.
A subset of participants from A5336 (N=36, 509 samples) and A5337 (N=8, 126 samples) were co-enrolled in this study (A5351s). Genital secretions, oral swabs, and urine were assayed for CMV DNA by qPCR at baseline and longitudinally (5 timepoints over 12 weeks for A5336; 6 timepoints over 44 weeks for A5337). Immunological biomarkers from A5336 included IL-6, sCD14, Ki67+, and CD38+HLA-DR+ on T-cells. Correlations between CMV DNA and biomarkers were examined at study entry and week 5 and 10 by Spearman’s correlations.
Median participant age was 49 years (range: 25-62), 77% were male sex (at birth) and 47% black race, non-Hispanic. Median baseline CD4+ T-cells were 859 cells/mm3. CMV DNA was detected in 45 genital (29%), 19 oral (11%), and 31 urine (18%) samples and was more commonly detected in men than in women (31% vs 3%). There was no apparent effect of either immune-modulatory intervention on CMV DNA (detectability or levels) at any mucosal site over time or between arms (all P values >0.1). Detectable CMV DNA in all post-baseline time points in A5336 was 25% in the placebo arm and 31% in the ruxolitinib arm (genital secretion), 8% and 13% (oral swabs), and 24% and 15% (urine). Similarly, no difference in CMV DNA was found pre and post Sirolimus for A5337. Within A5336, there was a consistent positive association between CMV DNA and Ki67+ on CD4+ and CD8+ T-cells (r between 0.30-0.62) and CD38+HLA-DR+CD8+ T-cells (r between 0.31-0.37) at multiple time points and from multiple sample sites (see Table 1).
Our pilot study did not observe any significant effect of immune-modulators on CMV DNA in PWH on ART with high baseline CD4+ T-cells. We did observe a consistent association between CMV levels and immune activation and cycling of CD4+ and CD8+ T-cells, which could have implications for HIV persistence (through expansion of CD4+ T-cells) and HIV-associated morbidity (through expansion of CD8+ T-cells as lower CD4+/CD8+ T-cell ratio is predictive of poor clinical outcome).